Compare TRTX & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRTX | CSTL |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 659.4M | 640.6M |
| IPO Year | N/A | 2019 |
| Metric | TRTX | CSTL |
|---|---|---|
| Price | $8.37 | $23.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $9.83 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 685.5K | 347.7K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 11.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $8.78 | $2.42 |
| Revenue Next Year | $4.14 | $12.69 |
| P/E Ratio | $14.82 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $7.57 | $14.59 |
| 52 Week High | $9.85 | $44.28 |
| Indicator | TRTX | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 63.90 |
| Support Level | $8.35 | $23.21 |
| Resistance Level | $8.73 | $24.33 |
| Average True Range (ATR) | 0.14 | 0.84 |
| MACD | -0.02 | 0.45 |
| Stochastic Oscillator | 26.53 | 80.79 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.